Analyst Ratings for Vertex Pharmaceuticals
Portfolio Pulse from Benzinga Insights
In the last quarter, Vertex Pharmaceuticals (NASDAQ:VRTX) received 6 bullish, 5 somewhat bullish, and 6 indifferent analyst ratings. The company's average 12-month price target is $364.06, up 13.06% from the previous average of $322.00.
June 22, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Vertex Pharmaceuticals received mixed analyst ratings in the last quarter, with an average 12-month price target of $364.06, up 13.06% from the previous average.
The mixed analyst ratings for Vertex Pharmaceuticals indicate that there is no clear consensus on the stock's short-term direction. The average 12-month price target has increased by 13.06%, which may suggest a positive outlook, but the presence of indifferent ratings adds uncertainty to the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100